European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies
Executive Summary
Worries about science bases drew European politicians to the AstraZeneca/Pfizer merger debate; the European industry calls for EU-wide R&D agenda, standards of care; IMI2 public-private partnership gets under way; FDA and EMA to collaborate on clinical trials for childhood Gaucher disease.
You may also be interested in...
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Pfizer Uses Layered Knowledge Management To Guide Tech Transfers
Pfizer has developed a multilayered knowledge management program that aims to ease the tech transfer process by harnessing institutional knowledge into one place. The program allows employees to ensure that processes remain stable during tech transfer by exploring all available process knowledge available on the product.
EFPIA Urges Drug Makers To See Value In Mobile Apps
The head of EFPIA believes drug makers are squandering opportunities offered by mobile health applications, a key point in the European trade body’s new manifesto.